Why Cencora ( COR ) is a Top Growth Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
What Does the Market Think About Cencora? - Cencora ( NYSE:COR )
Cencora's COR short interest as a percent of float has fallen 9.62% since its last report. According to exchange reported data, there are now 6.14 million shares sold short, which is 5.45% of all regular shares that are available for trading.
Cencora ( COR ) is a Top-Ranked Value Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
$1000 Invested In Cencora 10 Years Ago Would Be Worth This Much Today - Cencora ( NYSE:COR )
Cencora COR has outperformed the market over the past 10 years by 7.48% on an annualized basis producing an average annual return of 20.51%. Currently, Cencora has a market capitalization of $56.22 billion.
Should SPDR Russell 1000 Low Volatility Focus ETF ( ONEV ) Be on Your Investing Radar?
Style Box ETF report for ...
Is SPDR Russell 1000 Low Volatility Focus ETF ( ONEV ) a Strong ETF Right Now?
Smart Beta ETF report for ...
PACS Group, Inc. ( PACS ) Soars 24.5%: Is Further Upside Left in the Stock?
PACS Group, Inc. (PACS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why You Should Hold Cencora Stock in Your Portfolio Now
COR gains from strong GLP-1 and specialty drug growth, but margin pressure and fierce competition pose risks.
Here's Why Cencora ( COR ) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
If You Invested $1000 In This Stock 10 Years Ago, You Would Have This Much Today - Cencora ( NYSE:COR )
Cencora COR has outperformed the market over the past 10 years by 7.34% on an annualized basis producing an average annual return of 20.01%. Currently, Cencora has a market capitalization of $56.54 billion.
COR vs. MEDP: Which Stock Is the Better Value Option?
Investors with an interest in Medical Services stocks have likely encountered both Cencora ( COR Quick QuoteCOR - ) and Medpace ( MEDP Quick QuoteMEDP - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.
Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns
The GARP strategy helps investors gain exposure to stocks that have solid prospects and are trading at a discount. GE, HWM, COR and CAKE are some such stocks.
Cencora ( COR ) is an Incredible Growth Stock: 3 Reasons Why
Cencora (COR) possesses solid growth attributes, which could help it handily outperform the market.
Looking Into Cencora's Recent Short Interest - Cencora ( NYSE:COR )
Cencora's COR short percent of float has fallen 9.02% since its last report. The company recently reported that it has 6.48 million shares sold short, which is 5.75% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.81 days to cover their ...
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is Climb Bio, Inc. ( CLYM ) Outperforming Other Medical Stocks This Year?
Here is how Climb Bio, Inc. (CLYM) and Cencora (COR) have performed compared to their sector so far this year.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's How Much $100 Invested In Cencora 5 Years Ago Would Be Worth Today - Cencora ( NYSE:COR )
Cencora COR has outperformed the market over the past 5 years by 10.59% on an annualized basis producing an average annual return of 24.24%. Currently, Cencora has a market capitalization of $56.77 billion.
Global Ophthalmology Drugs Market to Reach USD 26.28 Billion by 2030 | MarketsandMarkets™
Delray Beach, FL, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- North America leads market expansion as companies advance next-generation ophthalmic therapies to address rising prevalence of vision-threatening diseases The global ophthalmology drugs market, valued at US$18.34 billion in 2024, stood at ...
Why Cencora ( COR ) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Outlook Therapeutics Reports Q3 Revenue
Outlook Therapeutics ( NASDAQ:OTLK ) , a biopharmaceutical company focused on ophthalmic treatments, released its third quarter fiscal 2025 results on August 14, 2025. The company posted its first-ever commercial revenue from European sales of LYTENAVA ( bevacizumab gamma ) , reaching $1.5 ...
Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update
ISELIN, N.J., Aug. 14, 2025 ( GLOBE NEWSWIRE ) -- Outlook Therapeutics, Inc. ( Nasdaq: OTLK ) , a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today reported financial results for the third quarter of fiscal year 2025 ...
Decoding Cardinal Health's Options Activity: What's the Big Picture? - Cardinal Health ( NYSE:CAH )
Whales with a lot of money to spend have taken a noticeably bullish stance on Cardinal Health. Looking at options history for Cardinal Health CAH we detected 25 trades. If we consider the specifics of each trade, it is accurate to state that 60% of the investors opened trades with bullish ...
3 Reasons Growth Investors Will Love Cencora ( COR )
Cencora (COR) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Can Sustained Product Demand Drive CAH Stock Before Q4 Earnings?
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal fourth-quarter revenues despite an uncertain macroeconomic environment.
ZBH Stock Gains On Q2 Earnings and Revenue Beat, '25 EPS View Up
Zimmer Biomet gains as Q2 earnings and revenues top estimates. full-year EPS guidance raised on strong segment growth.
STE Beats on Q1 Earnings and Revenues, Raises '26 Sales View
STERIS posts 15% EPS growth and raises FY26 revenue outlook, with all segments showing solid year-over-year gains.
What's Going On With Cencora Stock Wednesday? - Cencora ( NYSE:COR )
Q3 sales rose 8.7% to $80.66 billion, beating the $80.35 billion estimate; adjusted EPS grew 19.8% to $4.00. Full-year adjusted EPS guidance raised to $15.85-$16.00 from $15.70-$15.95. Get special access to three exclusive "Top 10 Stocks" power lists today, updated daily. Cencora, Inc.
COR Q3 Earnings & Revenues Beat Estimates, '25 EPS View Raised
Cencora posts strong Q3 results with earnings and revenues surpassing estimates. raises FY25 EPS guidance on robust U.S. segment growth.
CRL Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 View
Charles River shares jump 9.3% pre-market after Q2 earnings and revenues beat estimates. The company raises its 2025 outlook.
Cencora ( COR ) Q3 Earnings and Revenues Surpass Estimates
Cencora (COR) delivered earnings and revenue surprises of +5.82% and +0.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Henry Schein Stock Falls on Q2 Earnings Miss, Revenues Top
HSIC slides after Q2 EPS misses estimates by 6.8%. Revenues beat with 3.2% growth and strength across key segments.
Can Specialty and GLP-1 Momentum Support Cencora's Q3 Results?
COR benefits from strong specialty and GLP-1 demand, but Q3 results may face pressure from international weakness.
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today - Cencora ( NYSE:COR )
Cencora COR has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.65%. Currently, Cencora has a market capitalization of $55.89 billion.
DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?
XRAY's Imaging strength and SureSmile growth might have lifted Q2 performance, but Byte's drag and macro pressures likely clouded the top-line momentum.
Zimmer Biomet to Report Q2 Earnings: Here's What to Expect
ZBH's Q2 results may show strength in Hips, Knees, and S.E.T. despite a projected year-over-year earnings dip.
Gear Up for Cencora ( COR ) Q3 Earnings: Wall Street Estimates for Key Metrics
Beyond analysts' top-and-bottom-line estimates for Cencora (COR), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.
SYK Stock Falls Despite Q2 Earnings & Sales Beat, '25 View Up
SYK's second-quarter results reflect strong segmental performance, along with a rise in operating margin.
Will Healthcare Growth Help STE Beat on Q1 Earnings?
STERIS is likely to have experienced a strong Q1 with 14.3% EPS growth as Healthcare and AST segments show solid momentum.
BAX Stock Falls Following Q2 Earnings & Sales Miss, '25 EPS View Down
Baxter misses on Q2 earnings and sales, trims full-year EPS view, and posts weaker gross margin. Shares slide nearly 9% pre-market.
CVS Stock Up on Q2 Earnings & Revenue Beat, '25 EPS View Raised
CVS Health beats on Q2 earnings and raises 2025 EPS outlook, lifting shares nearly 8% on strong segment growth and margin gains.
Progyny ( PGNY ) Earnings Expected to Grow: Should You Buy?
Progyny (PGNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DexCom Stock Falls Despite Q2 Earnings Beat & 2025 Sales View Raise
DXCM beats on Q2 earnings and raises 2025 sales guidance, but shares dip as margin pressure dampens investor enthusiasm.
ALGN Stock Falls on Q2 Earnings and Revenue Miss, Margins Down
Align Technology tumbles 34.2% after Q2 earnings and revenues miss estimates as Clear Aligner sales drop and margins tighten further.
Cencora ( COR ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Charles River Q2 Earnings Preview: What's in Store for the Stock?
CRL gears up for Q2 earnings with expected revenue and EPS declines amid mixed segment performance.
Teladoc ( TDOC ) Reports Q2 Loss, Beats Revenue Estimates
Teladoc (TDOC) delivered earnings and revenue surprises of +29.63% and +1.77%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
WGS Stock Gains on Q2 Earnings and Revenue Beat, Raises '25 Sales View
GeneDx reports strong Q2 results with record revenues and surging profits. A raised 2025 sales outlook fuels a 26% stock jump.
Are Medical Stocks Lagging McKesson ( MCK ) This Year?
Here is how McKesson (MCK) and Cencora (COR) have performed compared to their sector so far this year.
